-
HS Pharmaceuticals, LLC is an early stage drug development company focusing on innovative immunotherapies for cancer treatment. Current pipeline programs include pre-clinical stage compounds for melanoma, pancreatic, breast, and lung cancers. HS Pharma's novel, proprietary, patented compound HS-7, is an orally available small molecule that also lends itself to IV systemic delivery with demonstrated safety and efficacy in animal models. The company is seeking US and international development partners. The company has a streamlined operational structure and utilizes best in class academic research labs, CRO's and industry experts to cost effectively advance its technology through the pre-clinical development process and into clinical trials. -
The HFACS framework helps our clients improve human performance among their employees. In the context of safety, this results in less on-the-job injuries and improved workplace safety. The HFACS framework was developed by Dr. Douglas Wiegmann and Dr. Scott Shappell in the United States Navy to identify why accidents were continuing to happen and how to reduce the accident rate. -
Established in September 2008 Hoowaki is a start-up company focusing on the development and commercialization of surface transformation technology. Using a low cost, proprietary route Hoowaki can mold micron-sized features on the surfaces of metals, ceramics and polymers. These features or patterns of features can be designed to provide surface properties that are independent of the bulk material. Such properties can affect appearance, touch, color, friction, adhesion, lubrication, drag and flow control.